Abstract:A principal goal of drug discovery project is to design molecules that can tightly and selectively bind to the target protein receptor. Accurate prediction of protein-ligand binding free energies is therefore of central importance in computational chemistry and computer aided drug design. Multiple recent improvements in computing power, classical force field accuracy, enhanced sampling methods, and simulation setup have enabled accurate and reliable calculations of protein-ligands binding free energies, and position free energy calculations to play a guiding role in small molecule drug discovery. In this Account, we outline the relevant methodological advances, including the REST2 (Replica Exchange with Solute Temperting) enhanced sampling, the incorporation of REST2 sampling with convential FEP (Free Energy Perturbation) through FEP/REST, the OPLS3 force field, and the advanced simulation setup that constitute our FEP+ approach, followed by the presentation of extensive comparisons with experiment, demonstrating sufficient accuracy in potency prediction (better than 1 kcal/mol) to substantially impact lead optimization campaigns. The limitations of the current FEP+ implementation and best practices in drug discovery applications are also discussed followed by the future methodology development plans to address those limitations. We then report results from a recent drug discovery project, in which several thousand FEP+ calculations were successfully deployed to simultaneously optimize potency, selectivity, and solubility, illustrating the power of the approach to solve challenging drug design problems. The capabilities of free energy calculations to accurately predict potency and selectivity have led to the advance of ongoing drug discovery projects, in challenging situations where alternative approaches would have great difficulties. The ability to effectively carry out projects evaluating tens of thousands, or hundreds of thousands, of proposed drug candidates, is potentially transformative in enabling hard to drug targets to be attacked, and in facilitating the development of superior compounds, in various dimensions, for a wide range of targets. More effective integration of FEP+ calculations into the drug discovery process will ensure that the results are deployed in an optimal fashion for yielding the best possible compounds entering the clinic; this is where the greatest payoff is in the exploitation of computer driven design capabilities. A key conclusion from the work described is the surprisingly robust and accurate results that are attainable within the conventional classical simulation, fixed charge paradigm. No doubt there are individual cases that would benefit from a more sophisticated energy model or dynamical treatment, and properties other than protein-ligand binding energies may be more sensitive to these approximations. We conclude that an inflection point in the ability of MD simulations to impact drug discovery has now been attained, due to the confluence of hardware and software development along with the formulation of "good enough" theoretical methods and models.

Enabling structure-based drug discovery utilizing predicted models

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Advancing Drug Discovery through Enhanced Free Energy Calculations

Advancing Drug Discovery with Accurate and Reliable Protein-Ligand Binding Free Energy Calculations

FEP Augmentation as a Means to Solve Data Paucity Problems for Machine Learning in Chemical Biology

Modeling Local Structural Rearrangements Using FEP/REST: Application to Relative Binding Affinity Predictions of CDK2 Inhibitors

Towards Structure-Based Protein Drug Design

Scaffold Hopping and Optimization of Small Molecule Soluble Adenyl Cyclase Inhibitors Led by Free Energy Perturbation

Leveraging nonstructural data to predict structures and affinities of protein-ligand complexes

Integrated Molecular Modeling and Machine Learning for Drug Design

Molecular Docking and Structure-Based Drug Design Strategies

Structure-based drug design: aiming for a perfect fit

Leveraging non-structural data to predict structures of protein–ligand complexes

Free energy perturbation (FEP)-guided scaffold hopping

Harnessing free energy calculations to achieve kinome-wide selectivity in drug discovery campaigns: Wee1 case study

Polyphony: superposition independent methods for ensemble-based drug discovery

Structure-based drug design: From nucleic acid to membrane protein targets

Fragment-Based Ligand Generation Guided By Geometric Deep Learning On Protein-Ligand Structure

Accurate Prediction of GPCR Ligand Binding Affinity with Free Energy Perturbation

New trends in computational structure prediction of ligand-protein complexes for receptor-based drug design

Fragmenstein: predicting protein-ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding–based methodology